Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 116

Sort by

Sort Order Select

Journal Articles

Infection risk factors and burden in patients treated with T-cell engaging bispecific antibodies for relapsed B-cell lymphoma and multiple myeloma

Blood (2025) 146 (Supplement 1): 2814.

https://doi.org/10.1182/blood-2025-2814

Published: 2025

Journal Articles

Allogeneic stem cell transplant results in t-cell prolymphocytic leukemia (T-PLL): A collaborative multi-center study cohort

Blood (2025) 146 (Supplement 1): 1054.

https://doi.org/10.1182/blood-2025-1054

Published: 2025

Journal Articles

Efficacy and safety of long-term odronextamab treatment in patients with relapsed/refractory follicular lymphoma: 3-year follow-up from the Phase 2 ELM-2 study

Jose Villasboas Bisneto, Deepa Jagadeesh, Don Stevens, Michal Taszner, Jingxian Cai, Amulya Uppala, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Manjusha Namuduri, Geoffrey Chong

Blood (2025) 146 (Supplement 1): 3588.

https://doi.org/10.1182/blood-2025-3588

Published: 2025

Journal Articles

Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up

Blood (2025) 146 (Supplement 1): 2115.

https://doi.org/10.1182/blood-2025-2115

Published: 2025

Journal Articles

A pilot study of nicotinamide riboside supplementation in allogeneic bone marrow transplantation

Ronald Sobecks, Navneet Majhail, Xiaorong Gu, Xuefei Jia, Megan Molnar, John Desamito, Dongxu Jiang, Kacey O'Donnell, Songa Bae, Craig Sauter, Andrew Trunk, Deepa Jagadeesh, Matt Kalaycio, Betty K. Hamilton, Claudio Brunstein, Jaroslaw Maciejewski, Babal Jha

Blood (2025) 146 (Supplement 1): 2437.

https://doi.org/10.1182/blood-2025-2437

Published: 2025

Journal Articles

Real-time interleukin-6 (IL-6) kinetics predict cytokine release syndrome (CRS) in patients receiving chimeric antigen receptor (CAR) T-cell therapy for Relapsed/Refractory B-cell malignancies

Agrima Mian, Rafaella Ferreira De Araujo Litvin, Jessica Colon-Franco, Sujata Patil, Megan Molnar, Allison Winter, Sandra Mazzoni, Robert Dean, Louis Williams, Aaron Gerds, John Molina, Shahzad Raza, Faiz Anwer, Deepa Jagadeesh, Betty K. Hamilton, Claudio Brunstein, Brian Hill, Paolo Caimi

Blood (2025) 146 (Supplement 1): 2397.

https://doi.org/10.1182/blood-2025-2397

Published: 2025

Journal Articles

Prognostic factors and survival outcomes of urgent inpatient chemotherapy for relapsed/refractory lymphoma in the modern era

Abhishek Kataria, Mikhaila Rice, Wei Wei, Faiz Anwer, Paolo Caimi, Allison Winter, Robert Dean, Taylor Brooks, Joslyn Rudoni, Jack Khouri, Christy Samaras, Shahzad Raza, Sandra Mazzoni, Jason Valent, Brian Hill, Deepa Jagadeesh

Blood (2025) 146 (Supplement 1): 2737.

https://doi.org/10.1182/blood-2025-2737

Published: 2025

Journal Articles

Outcomes of urgent inpatient chemotherapy for relapsed/refractory multiple myeloma in the modern era

Blood (2025) 146 (Supplement 1): 4601.

https://doi.org/10.1182/blood-2025-4601

Published: 2025

Journal Articles

Severe neutropenia after treatment with T-cell engaging bispecific antibodies is associated with higher rates of CRS and disease response

Blood (2025) 146 (Supplement 1): 6350.

https://doi.org/10.1182/blood-2025-6350

Published: 2025

Journal Articles

A multicenter real-world analysis (RWA) of primary cutaneous anaplastic large cell lymphoma (PCALCL) treated in the era of targeted therapies

Deepa Jagadeesh, Stefan Barta, Seunghee Margevicius, Jonathan Brammer, Jeanette Comstock, Pingfu Fu, Rahul Mishra, Montreh Tavakkoli, Alma Habib, Imran Nizamuddin, Tiffany Chang, Melissa Pulitzer, Cesar Virgen, Sharina Macapagal, Madiha Iqbal, N. Nora Bennani, Frederick Lansigan, Neha Mehta-Shah, Zachary Epstein-Peterson

Blood (2025) 146 (Supplement 1): 5433.

https://doi.org/10.1182/blood-2025-5433

Published: 2025

Journal Articles

Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 570.

https://doi.org/10.1182/blood-2024-199845

Published: 2024

Journal Articles

Assessment of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplant When Comparing Treatment with and without Post-Transplant Cyclophosphamide

Daniel P. Nurse, Wei Wei, Amanda Burns, Joseph Farinella, Deepa Jagadeesh, Robert M. Dean, Rabi Hanna, Seth J Rotz, Aaron T. Gerds, Claudio Brunstein, Matt Kalaycio, Craig S. Sauter, Betty K. Hamilton, Ronald Sobecks

Blood (2024) 144 (Supplement 1): 7383.

https://doi.org/10.1182/blood-2024-202626

Published: 2024

Journal Articles

Outcomes of Waldenström Macroglobulinemia Patients Requiring Therapeutic Plasma Exchange. Higher Rates of Progression and Resistance of Initial Systemic Therapy

Jessica Leng, Jack Khouri, Allison M. Winter, Deepa Jagadeesh, Robert M. Dean, Taylor R. Brooks, Louis Williams, Faiz Anwer, Craig S. Sauter, Brian T. Hill, Paolo F. Caimi

Blood (2024) 144 (Supplement 1): 6342.

https://doi.org/10.1182/blood-2024-206344

Published: 2024

Journal Articles

Matching-Adjusted Indirect Comparisons (MAICs) of Odronextamab Versus Mosunetuzumab and Epcoritamab for the Treatment of Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) after Two or More Lines of Systemic Therapy

Deepa Jagadeesh, Silvana Novelli, Stefano Luminari, Michal Taszner, Michele Merli, Yingzxin Xu, Siddhesh Kamat, Liza Mastikhina, Srikanth Ambati, Jenny Chen, Keith Chan, Shannon Cope, Sam Keeping, Clyde Caisip, Hesham Mohamed, Aafia Chaudhry, James Harnett, Jose C. Villasboas Bisneto

Blood (2024) 144 (Supplement 1): 7803.

https://doi.org/10.1182/blood-2024-200865

Published: 2024

Journal Articles

Global Incidence, Mortality and Risk Factors of Hodgkins and Non-Hodgkins Lymphoma 1990-2021: A Global Health Data Study

Rupayan Kundu, Niladri Kal, Abhay Singh, Deepa Jagadeesh

Blood (2024) 144 (Supplement 1): 6360.

https://doi.org/10.1182/blood-2024-212117

Published: 2024

Journal Articles

A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 459.

https://doi.org/10.1182/blood-2024-204113

Published: 2024

Journal Articles

Loncastuximab Tesirine in Combination with Venetoclax Is Safe and Shows Efficacy in Patients with Relapsed/Refractory Non Hodgkin Lymphoma

Paolo F. Caimi, Allison M. Winter, Robert M. Dean, Taylor R. Brooks, Deepa Jagadeesh, Craig S. Sauter, Brian T. Hill

Blood (2024) 144 (Supplement 1): 4499.

https://doi.org/10.1182/blood-2024-202154

Published: 2024

Journal Articles

Real World Experience with Time Limited Venetoclax and Obinutuzumab (VO) for Frontline Treatment of CLL/SLL with MRD Determination By Clonoseq®

Allison M. Winter, Olivia Landever, Hiruni Mendries, Willem Van Heeckeren, Chieh-Lin Fu, Robert M. Dean, Taylor R. Brooks, Deepa Jagadeesh, Paolo F. Caimi, Brian T. Hill

Blood (2024) 144 (Supplement 1): 3247.

https://doi.org/10.1182/blood-2024-200306

Published: 2024

Journal Articles

A Multicenter Real-World Analysis (RWA) of Primary Cutaneous Anaplastic Large Cell Lymphoma (PCALCL) Treated in the Modern Era

Deepa Jagadeesh, Stefan K. Barta, Jonathan E. Brammer, Wei Wei, Julie E Chang, Rahul Mishra, Tavakkoli Montreh, Alma Habib, Marcus P Watkins, Yash Deshmukh, Sharina C Macapagal, Madiha Iqbal, N. Nora Bennani, Frederick Lansigan, Neha Mehta-Shah

Blood (2023) 142 (Supplement 1): 6177.

https://doi.org/10.1182/blood-2023-191176

Published: 2023

Journal Articles

Safety Results of a Phase I Study of Zandelisib + R-CHOP in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL)

Deepa Jagadeesh, Paolo Caimi, Allison Winter, Wei Wei, Brad Pohlman, Christopher D'Andrea, Emily Rhoades, Robert M. Dean, Brian T. Hill

Blood (2023) 142 (Supplement 1): 6233.

https://doi.org/10.1182/blood-2023-191345

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Infection risk factors and burden in patients treated with T-cell engaging bispecific antibodies for relapsed B-cell lymphoma and multiple myeloma

Allogeneic stem cell transplant results in t-cell prolymphocytic leukemia (T-PLL): A collaborative multi-center study cohort

Efficacy and safety of long-term odronextamab treatment in patients with relapsed/refractory follicular lymphoma: 3-year follow-up from the Phase 2 ELM-2 study

Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up

A pilot study of nicotinamide riboside supplementation in allogeneic bone marrow transplantation

Real-time interleukin-6 (IL-6) kinetics predict cytokine release syndrome (CRS) in patients receiving chimeric antigen receptor (CAR) T-cell therapy for Relapsed/Refractory B-cell malignancies

Prognostic factors and survival outcomes of urgent inpatient chemotherapy for relapsed/refractory lymphoma in the modern era

Outcomes of urgent inpatient chemotherapy for relapsed/refractory multiple myeloma in the modern era

Severe neutropenia after treatment with T-cell engaging bispecific antibodies is associated with higher rates of CRS and disease response

A multicenter real-world analysis (RWA) of primary cutaneous anaplastic large cell lymphoma (PCALCL) treated in the era of targeted therapies

Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma

Assessment of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplant When Comparing Treatment with and without Post-Transplant Cyclophosphamide

Outcomes of Waldenström Macroglobulinemia Patients Requiring Therapeutic Plasma Exchange. Higher Rates of Progression and Resistance of Initial Systemic Therapy

Matching-Adjusted Indirect Comparisons (MAICs) of Odronextamab Versus Mosunetuzumab and Epcoritamab for the Treatment of Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) after Two or More Lines of Systemic Therapy

Global Incidence, Mortality and Risk Factors of Hodgkins and Non-Hodgkins Lymphoma 1990-2021: A Global Health Data Study

A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma

Loncastuximab Tesirine in Combination with Venetoclax Is Safe and Shows Efficacy in Patients with Relapsed/Refractory Non Hodgkin Lymphoma

Real World Experience with Time Limited Venetoclax and Obinutuzumab (VO) for Frontline Treatment of CLL/SLL with MRD Determination By Clonoseq®

A Multicenter Real-World Analysis (RWA) of Primary Cutaneous Anaplastic Large Cell Lymphoma (PCALCL) Treated in the Modern Era

Safety Results of a Phase I Study of Zandelisib + R-CHOP in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only